Increased PD-L1 Expression in HER2-Positive Breast Cancer without Pathologic Complete Response to Neoadjuvant Therapy

被引：0
|
作者：
Yang, Fei [1 ]
Song, Juhee [2 ]
Mino, Barbara [1 ]
Parra, Edwin R. [1 ]
Sahin, Aysegul [2 ]
Wistuba, Ignacio [2 ]
Litton, Jennifer [2 ]
Mittendorf, Elizabeth [2 ]
Wu, Yun
机构：
[1] UT MD Anderson Canc Ctr, Houston, TX USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
LABORATORY INVESTIGATION | 2018年 / 98卷
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
321
引用
收藏
页码：114 / 114
页数：1
相关论文
共 50 条
  • [31] Pathologic complete response of ductal carcinoma in situ to neoadjuvant systemic therapy in HER2-positive invasive breast cancer patients: a nationwide analysis
    Ploumen, Roxanne A. W.
    Claassens, Eva L.
    Kooreman, Loes F. S.
    Keymeulen, Kristien B. M. I.
    van Kats, Maartje A. C. E.
    Gommers, Suzanne
    Siesling, Sabine
    van Nijnatten, Thiemo J. A.
    Smidt, Marjolein L.
    BREAST CANCER RESEARCH AND TREATMENT, 2023, 201 (02) : 227 - 235
  • [32] Association of Pathologic Complete Response to Neoadjuvant Therapy in HER2-Positive Breast Cancer With Long-Term Outcomes A Meta-Analysis
    Broglio, Kristine R.
    Quintana, Melanie
    Foster, Margaret
    Olinger, Melissa
    McGlothlin, Anna
    Berry, Scott M.
    Boileau, Jean-Francois
    Brezden-Masley, Christine
    Chia, Stephen
    Dent, Susan
    Gelmon, Karen
    Paterson, Alexander
    Rayson, Daniel
    Berry, Donald A.
    JAMA ONCOLOGY, 2016, 2 (06) : 751 - 760
  • [33] Pathologic complete response of ductal carcinoma in situ to neoadjuvant systemic therapy in HER2-positive invasive breast cancer patients: a nationwide analysis
    Roxanne A. W. Ploumen
    Eva L. Claassens
    Loes F. S. Kooreman
    Kristien B. M. I. Keymeulen
    Maartje A. C. E. van Kats
    Suzanne Gommers
    Sabine Siesling
    Thiemo J. A. van Nijnatten
    Marjolein L. Smidt
    Breast Cancer Research and Treatment, 2023, 201 : 227 - 235
  • [34] Pathologic complete response (pCR) and prognosis following neoadjuvant chemotherapy plus anti-HER2 therapy of HER2-positive early breast cancer (EBC)
    Loibl, Sibylle
    Untch, Michael
    Buyse, Marc
    Robidoux, Andre
    Gianni, Luca
    Schneeweiss, Andreas
    Conte, Pierfranco
    Piccart, Martine
    Bonnefoi, Herve
    Jackisch, Christian
    Nekljudova, Valentina
    Costantino, Joseph
    Valagussa, Pinuccia
    Neate, Colin
    Gelber, Richard
    Poncet, Coralie
    Squifflet, Pierre
    Saad, Everardo
    Heinzmann, Dominik
    Denkert, Carsten
    Geyer, Charles E., Jr.
    Cortes, Javier
    Guarneri, Valentina
    de Azambuja, Evandro
    Cameron, David
    Ismael, Gustavo
    von Minckwitz, Gunter
    Wolmark, Norman
    Cortazar, Patricia
    CANCER RESEARCH, 2020, 80 (04)
  • [35] ASO Author Reflections: Inflammatory Breast Cancer: Durable Breast Cancer-Specific Survival for HER2-Positive Patients with a Pathologic Complete Response to Neoadjuvant Therapy
    Hieken, Tina J.
    Hoskin, Tanya L.
    ANNALS OF SURGICAL ONCOLOGY, 2022, 29 (SUPPL 3) : 597 - 598
  • [36] ASO Author Reflections: Inflammatory Breast Cancer: Durable Breast Cancer-Specific Survival for HER2-Positive Patients with a Pathologic Complete Response to Neoadjuvant Therapy
    Tina J. Hieken
    Tanya L. Hoskin
    Annals of Surgical Oncology, 2022, 29 : 597 - 598
  • [37] High Pathologic Complete Response in Her2-Positive, Early-Stage Breast Cancer to a Novel Nonanthracycline Neoadjuvant Chemotherapy
    Zelnak, Amelia B.
    Nikolinakos, Petros
    Srinivasiah, Jayanthi
    Jonas, William
    Pippas, Andrew
    Liu, Yuan
    Li, Xiaoxian
    Torres, Mylin
    O'Regan, Ruth M.
    CLINICAL BREAST CANCER, 2015, 15 (01) : 31 - 36
  • [38] Effect of Trastuzumab among HER2-Positive Breast Cancer Patients that Achieved Pathologic Complete Response after Neoadjuvant Chemotherapy
    Wang, Xinguang
    He, Yingjian
    Fan, Zhaoqing
    Wang, Tianfeng
    Xie, Yuntao
    Li, Jinfeng
    Ouyang, Tao
    BREAST CARE, 2019, 14 (06) : 388 - 393
  • [39] Pathologic Complete Response to Neoadjuvant Chemotherapy Plus Trastuzumab Predicts for Improved Survival in Women With HER2-positive Breast Cancer
    Kim, M. M.
    Allen, P.
    Gonzalez-Angulo, A.
    Woodward, W. A.
    Meric-Bernstam, F.
    Buzdar, A. U.
    Hunt, K. K.
    Hortobagyi, G. N.
    Buchholz, T. A.
    Mittendorf, E. A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 84 (03): : S229 - S229
  • [40] Predictive Factors of Response in HER2-Positive Breast Cancer Treated by Neoadjuvant Therapy
    Guiu, S.
    Reynier, M. A. Mouret
    Toure, M.
    Coudert, B.
    JOURNAL OF ONCOLOGY, 2013, 2013
12345